GIP and GLP-1 receptor co-agonist
VK2735 15 mg injection once weekly
VK2735_SC_15MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.75 (0.05 to 6.56) | 0.61 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 9.02 (1.68 to 61.86) | 0.15 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.19 (1.82 to 10.47) | 0.42 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 10.50 (2.32 to 60.30) | 0.22 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.17 (0.27 to 4.90) | 0.67 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.42 (0.74 to 8.63) | 0.43 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 3.66 (0.18 to 84.60) | 0.31 |